Oncolytics Biotech, Inc. (NASDAQ:ONCY) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET
Company Participants
Jon Patton - Director, Investor Relations and Communication
Matthew Coffey - President, CEO & Director
Thomas Heineman - Chief Medical Officer, Oncolytics Biotech (U.S.)
Kirk Look - CFO
Conference Call Participants
John Newman - Canaccord Genuity
Operator
Good afternoon and welcome to Oncolytics Biotech's First Quarter 2024 Conference Call. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead.
Jon Patton
Thank you, operator, and good afternoon, everyone. Earlier today, Oncolytics issued press release providing recent operational highlights and financial results for the first quarter of 2024. A replay of today's call will be available on the Events section of the Oncolytics website approximately two hours after its completion. After remarks from company management will open the call for Q&A.
As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of pelareorep, including statements regarding the company's mission, company's belief as an essential and mechanism of action of pelareorep as a cancer therapeutic.
Our belief that we are positioned to begin registrational track studies in breast and pancreatic cancer, and our strategies and upcoming milestones in connection therewith, our critical objectives through 2024 anticipated timing and the release of additional data companies believe that it has sufficient cash to achieve these milestones and other statements related spend built into the company's business.
These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or expectations implied by these forward-looking statements.
In any forward looking statements, which are politically expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis. But there can be no assurance that the statement or expectation or belief will be achieved.
These factors include results of current or pending clinical trials, risks associated intellectual property protection, financial projections, actions by regulatory agencies, and those other factors detailed in the company's filings with SEDAR and the SEC. I'm going to undertake undertake any obligation to update these forward-looking statements, except as required by applicable laws.